136 related articles for article (PubMed ID: 10640301)
1. Functional and molecular properties of the human recombinant Y4 receptor: resistance to agonist-promoted desensitization.
Voisin T; Goumain M; Lorinet AM; Maoret JJ; Laburthe M
J Pharmacol Exp Ther; 2000 Feb; 292(2):638-46. PubMed ID: 10640301
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization of (125)I-1229U91 binding to Y1 and Y4 neuropeptide Y/Peptide YY receptors.
Schober DA; Gackenheimer SL; Heiman ML; Gehlert DR
J Pharmacol Exp Ther; 2000 Apr; 293(1):275-80. PubMed ID: 10734179
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the peptide binding requirements for the cloned human pancreatic polypeptide-preferring receptor.
Gehlert DR; Schober DA; Beavers L; Gadski R; Hoffman JA; Smiley DL; Chance RE; Lundell I; Larhammar D
Mol Pharmacol; 1996 Jul; 50(1):112-8. PubMed ID: 8700103
[TBL] [Abstract][Full Text] [Related]
4. FMRFamides exert a unique modulation of rodent pancreatic polypeptide sensitive neuropeptide Y (NPY) receptors.
Parker SL; Parker MS
Can J Physiol Pharmacol; 2000 Feb; 78(2):150-61. PubMed ID: 10737678
[TBL] [Abstract][Full Text] [Related]
5. Characterization and regulation of the human ML1A melatonin receptor stably expressed in Chinese hamster ovary cells.
Witt-Enderby PA; Dubocovich ML
Mol Pharmacol; 1996 Jul; 50(1):166-74. PubMed ID: 8700109
[TBL] [Abstract][Full Text] [Related]
6. BODIPY-conjugated neuropeptide Y ligands: new fluorescent tools to tag Y1, Y2, Y4 and Y5 receptor subtypes.
Dumont Y; Gaudreau P; Mazzuferi M; Langlois D; Chabot JG; Fournier A; Simonato M; Quirion R
Br J Pharmacol; 2005 Dec; 146(8):1069-81. PubMed ID: 16231000
[TBL] [Abstract][Full Text] [Related]
7. Studies of the structure of the N-terminal domain from the Y4 receptor - a G protein-coupled receptor - and its interaction with hormones from the NPY family.
Zou C; Kumaran S; Markovic S; Walser R; Zerbe O
Chembiochem; 2008 Sep; 9(14):2276-84. PubMed ID: 18767100
[TBL] [Abstract][Full Text] [Related]
8. Internalization of cloned pancreatic polypeptide receptors is accelerated by all types of Y4 agonists.
Parker MS; Sah R; Sheriff S; Balasubramaniam A; Parker SL
Regul Pept; 2005 Dec; 132(1-3):91-101. PubMed ID: 16213038
[TBL] [Abstract][Full Text] [Related]
9. Identification of potent and selective neuropeptide Y Y(1) receptor agonists with orexigenic activity in vivo.
Mullins D; Kirby D; Hwa J; Guzzi M; Rivier J; Parker E
Mol Pharmacol; 2001 Sep; 60(3):534-40. PubMed ID: 11502885
[TBL] [Abstract][Full Text] [Related]
10. Neuropeptide Y and peptide YY inhibit lipolysis in human and dog fat cells through a pertussis toxin-sensitive G protein.
Valet P; Berlan M; Beauville M; Crampes F; Montastruc JL; Lafontan M
J Clin Invest; 1990 Jan; 85(1):291-5. PubMed ID: 2104880
[TBL] [Abstract][Full Text] [Related]
11. NPY receptor subtype in the rabbit isolated ileum.
Félétou M; Nicolas JP; Rodriguez M; Beauverger P; Galizzi JP; Boutin JA; Duhault J
Br J Pharmacol; 1999 Jun; 127(3):795-801. PubMed ID: 10401572
[TBL] [Abstract][Full Text] [Related]
12. Y(4) receptors mediate the inhibitory responses of pancreatic polypeptide in human and mouse colon mucosa.
Tough IR; Holliday ND; Cox HM
J Pharmacol Exp Ther; 2006 Oct; 319(1):20-30. PubMed ID: 16807358
[TBL] [Abstract][Full Text] [Related]
13. Role of the C terminus in neuropeptide Y Y1 receptor desensitization and internalization.
Holliday ND; Lam CW; Tough IR; Cox HM
Mol Pharmacol; 2005 Mar; 67(3):655-64. PubMed ID: 15576634
[TBL] [Abstract][Full Text] [Related]
14. Neuropeptide Y as a partial agonist of the Y1 receptor.
Sah R; Balasubramaniam A; Parker MS; Sallee F; Parker SL
Eur J Pharmacol; 2005 Nov; 525(1-3):60-8. PubMed ID: 16293244
[TBL] [Abstract][Full Text] [Related]
15. Neuropeptide Y, Y1, Y2 and Y4 receptors mediate Y agonist responses in isolated human colon mucosa.
Cox HM; Tough IR
Br J Pharmacol; 2002 Mar; 135(6):1505-12. PubMed ID: 11906964
[TBL] [Abstract][Full Text] [Related]
16. Evidence for the existence of an additional class of neuropeptide Y receptor sites in rat brain.
Dumont Y; Moyse E; Fournier A; Quirion R
J Pharmacol Exp Ther; 2005 Oct; 315(1):99-108. PubMed ID: 15947033
[TBL] [Abstract][Full Text] [Related]
17. Rat somatostatin receptor type 1 couples to G proteins and inhibition of cyclic AMP accumulation.
Hadcock JR; Strnad J; Eppler CM
Mol Pharmacol; 1994 Mar; 45(3):410-6. PubMed ID: 8145728
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a new neuropeptide Y Y5 agonist radioligand: [125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP.
Dumont Y; Thakur M; Beck-Sickinger A; Fournier A; Quirion R
Neuropeptides; 2004 Aug; 38(4):163-74. PubMed ID: 15337369
[TBL] [Abstract][Full Text] [Related]
19. Adenosine A1 receptor-dependent and -independent effects of the allosteric enhancer PD 81,723.
Musser B; Mudumbi RV; Liu J; Olson RD; Vestal RE
J Pharmacol Exp Ther; 1999 Feb; 288(2):446-54. PubMed ID: 9918544
[TBL] [Abstract][Full Text] [Related]
20. Strongly altered receptor binding properties in PP and NPY chimeras are accompanied by changes in structure and membrane binding.
Lerch M; Kamimori H; Folkers G; Aguilar MI; Beck-Sickinger AG; Zerbe O
Biochemistry; 2005 Jun; 44(25):9255-64. PubMed ID: 15966750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
